Gender-Based Sex Selection Practice on the Rise
By Deccan Herald,
Deccan Herald [India]
| 07. 29. 2014
A recent United Nations study has pointed out the worsening trend in gender based sex selection practices – elimination of girl child during pregnancy – in the country.
The study says that though the north-west region, which has been traditionally infested with the malady has reached a plateau as far as the Child Sex Ratio (CSR) in the age group of 0-6 is concerned, the problem has spread slowly across the country.
The report, which was recently released by UN-Women and authored by Mary E John of Centre for Women’s Studies, points out the shift in the 2011 census where the practice reached its peak in the north-west region, and was spreading in large parts of the country. The report says that the provisional results of Census 2011 have added new twists to the saga
Though CSR is still severe in the north-west, a slight improvement was observed. “It would appear that there has been a peaking (or plateauing) of the practice of sex selection in states like Gujarat, Haryana, Delhi and Himachal Pradesh with actual small improvements from very...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...